These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27151985)

  • 1. Variation of Specific Activities of 68Ga-Aquibeprin and 68Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins α5β1 and αvβ3.
    Notni J; Steiger K; Hoffmann F; Reich D; Schwaiger M; Kessler H; Wester HJ
    J Nucl Med; 2016 Oct; 57(10):1618-1624. PubMed ID: 27151985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin.
    Notni J; Steiger K; Hoffmann F; Reich D; Kapp TG; Rechenmacher F; Neubauer S; Kessler H; Wester HJ
    J Nucl Med; 2016 Mar; 57(3):460-6. PubMed ID: 26635338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
    Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Characterization of 4
    Lobeek D; Franssen GM; Ma MT; Wester HJ; Decristoforo C; Oyen WJG; Boerman OC; Terry SYA; Rijpkema M
    J Nucl Med; 2018 Aug; 59(8):1296-1301. PubMed ID: 29626124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366.
    D'Alessandria C; Pohle K; Rechenmacher F; Neubauer S; Notni J; Wester HJ; Schwaiger M; Kessler H; Beer AJ
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):953-963. PubMed ID: 26497698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice.
    Jeong JM; Hong MK; Chang YS; Lee YS; Kim YJ; Cheon GJ; Lee DS; Chung JK; Lee MC
    J Nucl Med; 2008 May; 49(5):830-6. PubMed ID: 18413379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃.
    Notni J; Pohle K; Wester HJ
    Nucl Med Biol; 2013 Jan; 40(1):33-41. PubMed ID: 22995902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry.
    Buchegger F; Viertl D; Baechler S; Dunet V; Kosinski M; Poitry-Yamate C; Rüegg C; Prior JO
    Nuklearmedizin; 2011; 50(6):225-33. PubMed ID: 21989840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison.
    Knetsch PA; Petrik M; Rangger C; Seidel G; Pietzsch HJ; Virgolini I; Decristoforo C; Haubner R
    Nucl Med Biol; 2013 Jan; 40(1):65-72. PubMed ID: 23102540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation.
    Knetsch PA; Zhai C; Rangger C; Blatzer M; Haas H; Kaeopookum P; Haubner R; Decristoforo C
    Nucl Med Biol; 2015 Feb; 42(2):115-22. PubMed ID: 25459110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process.
    Pohle K; Notni J; Bussemer J; Kessler H; Schwaiger M; Beer AJ
    Nucl Med Biol; 2012 Aug; 39(6):777-84. PubMed ID: 22444238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
    Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET-Based Human Dosimetry of the Dimeric αvβ3 Integrin Ligand 68Ga-DOTA-E-[c(RGDfK)]2, a Potential Tracer for Imaging Tumor Angiogenesis.
    López-Rodríguez V; Galindo-Sarco C; García-Pérez FO; Ferro-Flores G; Arrieta O; Ávila-Rodríguez MA
    J Nucl Med; 2016 Mar; 57(3):404-9. PubMed ID: 26585063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK).
    Simeček J; Notni J; Kapp TG; Kessler H; Wester HJ
    Mol Pharm; 2014 May; 11(5):1687-95. PubMed ID: 24669840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis.
    Haubner R; Finkenstedt A; Stegmayr A; Rangger C; Decristoforo C; Zoller H; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2005-13. PubMed ID: 27164900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo PET Imaging of the Cancer Integrin αvβ6 Using
    Notni J; Reich D; Maltsev OV; Kapp TG; Steiger K; Hoffmann F; Esposito I; Weichert W; Kessler H; Wester HJ
    J Nucl Med; 2017 Apr; 58(4):671-677. PubMed ID: 27980050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.